Genetic Disease Clinical Trial
— ReSTOfficial title:
A Study to Evaluate the Feasibility of Screening Relatives of Patients Affected by Non-Syndromic Thoracic Aortic Diseases: The ReST Study
Verified date | April 2021 |
Source | University of Leicester |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The primary hypothesis is that a tailored programme of genetic and imaging screening of first- and second-degree relatives of patients affected by non-syndromic forms of thoracic aortic diseases will identify individuals at risk of death from these conditions. These individuals would constitute specific population of patients, requiring dedicated imaging surveillance and/or earlier prophylactic aortic surgery.
Status | Active, not recruiting |
Enrollment | 70 |
Est. completion date | May 20, 2022 |
Est. primary completion date | May 20, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 16 Years and older |
Eligibility | Inclusion Criteria: 1. NS-TAD probands operated on (n=16). 2. FDR and SDR, aged 16 and above: 1. At least two relatives willing to participate in the screening programme. 2. Relatives able to understand English. Exclusion Criteria: 1. Probands with syndromic aortopathies, including Marfan Syndrome, Loeys-Dietz Syndrome, Ehlers-Danlos Syndrome, Shprintzen-Goldberg syndrome, aneurysm-osteoarthritis syndrome, arterial tortuosity syndrome, and cutis laxa syndrome. 2. Probands with aortic lesions associated with trauma and infections. 3. Probands/relatives unable to give informed consent |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Department of Cardiovascular Sciences | Leicester | Leicestershire |
Lead Sponsor | Collaborator |
---|---|
University of Leicester |
United Kingdom,
Mariscalco G, Debiec R, Elefteriades JA, Samani NJ, Murphy GJ. Systematic Review of Studies That Have Evaluated Screening Tests in Relatives of Patients Affected by Nonsyndromic Thoracic Aortic Disease. J Am Heart Assoc. 2018 Aug 7;7(15):e009302. doi: 10.1161/JAHA.118.009302. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Rate of genetic diagnosis | Frequency of first and second degree relatives with newly identified genetic loci associated with NS-TADs. | Through study completion, an average of 1 year | |
Primary | Rate of diagnosis through imaging modalities | Frequency of newly diagnosed TAD through imaging modalities in first- and second-degree relatives of probands affected by NS-TADs. | At the end of recruitment stage, an average of 6 months | |
Secondary | Genetic variants | Genetic variants associated with NS-TADs, identified from a panel of 55 loci, and rate of identification of each mutation. | Through study completion, an average of 1 year | |
Secondary | Family rate of genetic carriers | Rate of genetic carriers in each affected family. | Through study completion, an average of 1 year | |
Secondary | Penetrance | Genetic penetrance of the NS-TADs (proportion of individuals carrying a particular variant of a gene that are also affected by NS-TAD). | Through study completion, an average of 1 year | |
Secondary | Mode of inheritance | Pattern of inheritance of the NS-TADs. | Through study completion, an average of 1 year | |
Secondary | Male: female preponderance | Male: female preponderance of NS-TADs. | Through study completion, an average of 1 year | |
Secondary | Aortic Compliance | Measured as an MRI feature of affected and unaffected thoracic aortas. | Imaging tests completion, an average of 6 months. | |
Secondary | Aortic Distensibility | Measured as an MRI feature of affected and unaffected thoracic aortas. | Imaging tests completion, an average of 6 months. | |
Secondary | Rates of concomitant external and cardiovascular characteristics | Rates of concomitant cardiovascular diseases (e.g. patent ductus arteriosus, cerebrovascular aneurysm) and external physical features (e.g. pectus excavates, livedo reticularis). | Baseline clinical assessment | |
Secondary | Response rate | Response rates (recruitment) among the probands and their relatives. | Baseline clinical assessment | |
Secondary | Acceptability questionnaires | Semi-quantitative evaluation of the participant experience awareness and acceptability of the screening and consent process, obtained by questionnaires administered to the patients and relatives.
Scales will be composed by 10 items, each can be rated with a score from 1 to 5. No threshold will be preset. Descriptive statistics will be used to present the results. |
Baseline and 3 months follow up | |
Secondary | Depression evaluation | Semi-quantitative evaluation of the impact of the screening process on depression in probands and their relatives (baseline and 3 months), based on Patient Health Questionnaire (PHQ-9) score. Score range goes from 0 to 27, proposed cut-off for active treatment is 15. | Baseline and 3 months follow up | |
Secondary | Anxiety evaluation | Semi-quantitative evaluation of the impact of the screening process on anxiety in probands and their relatives (baseline and 3 months), based on Generalized Anxiety Disorder (GAD-7) score. Score range goes from 0 to 21, proposed cut-off for further assessment is 10. | Baseline and 3 months follow up | |
Secondary | Health-related Quality of Life evaluation | Semi-quantitative evaluation of the impact of the screening process on health-related quality of life in probands and their relatives (baseline and 3 months), based on Short Form (36) Health Survey (SF-36) score. Said questionnaire is made up of eight scales, which are the weighted sums of the items for each section; a score of zero corresponds to maximum disability while 100 correlates to no disability. | Baseline and 3 months follow up | |
Secondary | Resource use of genetic screening | Resource uses in terms of unitary costs of the genetic screening process. | 3 months follow up | |
Secondary | Resource use of imaging screening | Resource uses in terms of unitary costs of the imaging screening process. | 3 months follow up | |
Secondary | Resource use (hospital visits) | Number of participants reaching the research centre. | 3 months follow up |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03548779 -
North Carolina Genomic Evaluation by Next-generation Exome Sequencing, 2
|
N/A | |
Completed |
NCT03292302 -
Phase 1 Study of ELX-02 in Healthy Adults
|
Phase 1 | |
Withdrawn |
NCT03658382 -
Virtual Visits for Results Disclosure
|
N/A | |
Recruiting |
NCT02266615 -
Biobank Clinical Genetics Maastricht (KG01)
|
||
Recruiting |
NCT02450851 -
Clinical and Genetic Evaluation of Individuals With Undiagnosed Disorders Through the Undiagnosed Diseases Network
|
||
Recruiting |
NCT05472714 -
Educational Video for Genetic Testing
|
N/A | |
Recruiting |
NCT04285814 -
Technology Development for Noninvasive Prenatal Genetic Diagnosis Using Whole Fetal Cells From Maternal Peripheral Blood
|
||
Completed |
NCT05443113 -
Young Pectus Excavatum Patients and Genetic Defects
|
||
Completed |
NCT05655741 -
Modified Delphi for Genomic Bereavement Care
|
||
Completed |
NCT03847909 -
A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2
|
Phase 2 | |
Completed |
NCT04584528 -
Implementing an Individualized Pain Plan (IPP) for ED Treatment of VOE's in Sickle Cell Disease
|
N/A | |
Not yet recruiting |
NCT06048523 -
Prospective Cohort Study of Neurogenetic Diseases
|
N/A | |
Completed |
NCT02225522 -
Genomic Sequencing in Acutely Ill Neonates
|
N/A | |
Enrolling by invitation |
NCT06089954 -
Penn Medicine Biobank Return of Results Program
|
N/A | |
Completed |
NCT03713333 -
Implementing Digital Health in a Learning Health System
|
N/A | |
Completed |
NCT03309605 -
Phase 1 Study of ELX-02 in Healthy Adult Subjects
|
Phase 1 | |
Recruiting |
NCT05499091 -
Functional Study to Indentify Genetic Etiology of Rare Diseases - ORIGIN
|
N/A | |
Completed |
NCT04556487 -
Turkish Affordances in the Home Environment for Motor Development-Infant Scale (AHEMD-IS)
|
||
Completed |
NCT04556500 -
Turkish Version of the Affordance in the Home Environment for Motor Development-Toddler (AHEMD-T)
|
||
Recruiting |
NCT02551081 -
Genomic Sequencing and Personalized Treatment for Birth Defects in Neonatal Intensive Care Units
|